About Embio
Embio is a company based in Mumbai (India) founded in 1986. Embio has raised $50.29 million across 4 funding rounds from investors including UTI Mutual Fund and True North. The company has 600 employees as of April 05, 2024. Embio offers products and services including APIs, Intermediates, CDMO Services, and Crop Protection Products. Embio operates in a competitive market with competitors including Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
- Headquarter Mumbai, India
- Employees 600 as on 05 Apr, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Embio Limited
- Date of Incorporation 20 Jan, 1986
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$19.17 M (USD)-15.19as on Mar 31, 2022
-
Net Profit
$326.64 K (USD)-87.83as on Mar 31, 2022
-
EBITDA
$1.56 M (USD)-64.86as on Mar 31, 2022
-
Total Equity Funding
$50.29 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Private Equity Round
May 27, 2026
-
Investors
UTI Mutual Fund
& 1 more
-
Employee Count
600
as on Apr 05, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Embio
Embio offers a comprehensive portfolio of products and services, including APIs, Intermediates, CDMO Services, and Crop Protection Products.
Active ingredients for drug manufacturing and global supply
Raw materials for chemical synthesis processes
Custom development and manufacturing for client needs
Solutions for crop and plant protection improvement
People of Embio
Unlock access to complete
Funding Insights of Embio
Embio has successfully raised a total of $50.29M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $50 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Embio
Embio has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include UTI Mutual Fund and True North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Mutual funds, portfolio management, and retirement planning services are offered.
|
Locked | Locked | Locked |
Investor details for Embio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Embio
Investment portfolio details for Embio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Embio
Detailed financials for Embio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Embio Comparisons
Peer comparison for Embio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Embio
Embio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
Detailed competitors of Embio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Embio
Complete news archive for Embio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Embio
Embio was founded in 1986 and raised its 1st funding round 17 years after it was founded.
Embio is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Embio is a funded company, having raised a total of $50.29M across 4 funding rounds to date.
As of Apr 05, 2024, the latest employee count at Embio is 600.
Annual revenue of Embio is $19.17M as on Mar 31, 2022.
Embio is engaged in manufacturing APIs and chiral intermediates. It has a portfolio of 24 chiral intermediates and 13 API products. Core competencies include fermentationbiotransformation, chiral chemistry, catalytic hydrogenation and handing controlled substance. It has an array of fermenters 10L, 20L, 50L, 100L, 500L, 1000L, 2000L, 4000L for products of high value and low volume such as enzymes, APIs etc. for satisfying contract manufacturing requirements of its clients. Its manufacturing facility is approved by US-FDA, TGA, WHO-GMP and KFD. It has been complimented by DEA for adhering to documentation systems for controlled substance regulations. It has also been accredited with USP mark and certificate for Pseudoephedrine HCL.
Embio's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Embio offers APIs, Intermediates, CDMO Services, and Crop Protection Products.
Embio has 2 investors. Key investors include UTI Mutual Fund, and True North.